| Customization: | Available |
|---|---|
| Certification: | ISO, HACCP |
| Age Group: | Adults |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Benfotiamine is vitamin B1 fat soluble derivatives, improve the bioavailability of water-soluble vitamin B1 low shortcomings, improve the blood and tissue concentrations of thiamine, so as to improve the curative effect. Benfotiamine is primarily marketed as an antioxidant dietary supplement.
| Product name | Benfotiamine |
| Specification | 99% |
| Appearance | White powder |
| MOQ | 1kg |
| Sample | 1-2g |
| Shelf life | 2 years |
Benfotiamine is useful for the treatment of diabetic retinopathy, neuropathy, and nephropathy however "Most of the effects attributed to benfotiamine are extrapolated from in vitro and animal studies. Unfortunately apparent evidences from human studies are scarce and especially endpoint studies are missing. Therefore additional clinical studies are mandatory to explore the therapeutic potential of benfotiamine in both diabetic and non-diabetic pathological conditions".
It is thought that treatment with benfotiamine leads to increased intracellularthiamine diphosphate levels, a cofactor of transketolase. This enzyme directs advanced glycation and lipoxidation end products (AGE's, ALE's) substrates to the pentose phosphate pathway, thus reducing tissue AGEs.
Application
1. Benfotiamine is used for the prevention and treatment of vitamin B1 deficiency;
2. For vitamin B1 demand increase, with inadequate intake from foods supplies (fatigue, hyperthyroidism, pregnancy, lactation, during strenuous manual labor, etc.);
3. Benfotiamine is used in the treatment of non alcoholic wernicke encephalopathy;
4. To treat beriberi;
5. Used in the following diseases, speculation and vitamin B1 deficiency and metabolic disorders associated with treatment, such as: neuralgia; Muscle pain, joint pain; Peripheral neuritis, peripheral nerve palsy; Myocardial metabolic disorders; Constipation and other gastrointestinal motor function obstacle.
| Items | Requirements | Results |
| Physical & Chemical | ||
| Appearance | White powder | Conform |
| Odor | Characteristic | Characteristic |
| Particle Size | 98% pass 80mesh | Complies |
| Loss on Drying | ≤5.0% | 3.65% |
| Ash | ≤5.0% | 1.96% |
| Solvent Residue | Meet standard | Complies |
| Pesticide Residue | Meet standard | Complies |
| Microorganism | ||
| Total Plate Count | ≤1000cfu/g | Conform |
| Yeasts and Molds | ≤100cfu/g | Conform |
| Saimonella | Negative/25g | Conform |
| E.coli | Negative | Conform |
| Assay | 98% | 99.5% |
| Conclusion:This product conforms to the Enterprise standard. | ||
){kind=link}